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PCN5
FIRST-LINE THERAPY FOR ADVANCED BREAST 
CANCER — COST-EFFECTIVENESS OF 
ANASTROZOLE VERSUS TAMOXIFEN
Marchetti M1, Liberato N2, Barosi G1
1IRCCS Policlinico San Matteo, Pavia, Italy; 2Civil Hospital, 
Voghera, Italy, Pavia, Italy
OBJECTIVE: New generation nonsteroidal aromatase
inhibitors are potent, selective and well-tolerated anti-
estrogens that improve survival of advanced breast can-
cer patients when used as second-line agents. Anastro-
zole, an aromatase inhibitor, was recently investigated as
first-line therapy. Its cost, however, is 10 times higher
than the cost of tamoxifen. Consequently the cost-effec-
tiveness of anastrozole is to be investigated.
METHODS: We first addressed the cost per month-with-
out-progression with a three-state Markov tree (response;
progression; withdrawal) with monthly transitions. The
probability of progression was obtained by pooling the
data from estrogen-positive women enrolled into the
three randomized clinical trials. The monthly rate of
withdrawal was assumed to be time-independent and the
cost of withdrawal was equivalent to the approximate
charge for a thromboembolic event. According to the
Italian market, the monthly cost of tamoxifen was $18
and that of anastrozole, $190. No other difference in
costs was assumed between the two treatments.
RESULTS: Since anastrozole allowed for a gain of 1.77 pro-
gression-free months, the resulting marginal cost-effective-
ness of anastrozole versus tamoxifen was $1395/month-
without-progression. We then calculated the lag time
from progression to death and considered the average
monthly cost of those patients who progressed while on
first-line therapy to be $1000. The cost-effectiveness of
anastrozole was thus $19,428/life year saved, and, after
adjustment for quality of life, $33,476/QALY. The re-
sults were not sensitive to an increase in drug cost of
30%, while they were sensitive to a variation in the rela-
tive risk of progression.
CONCLUSION: Anastrozole is a cost-effective second
line therapy for post-menopausal women with advanced
breast cancer and positive for estrogen receptors. It is
also a potentially cost-effective first-line hormonal ther-
apy. Both clinical and economic data are needed from




OF DOCETAXEL IN THE SECOND LINE 
TREATMENT OF NON-SMALL-CELL
LUNG CANCER (NSCLC)
Sharplin P1, Bose UK1, Holmes J2
1Aventis Pharma UK, West Malling, Kent, UK; 2EAG, London, UK
OBJECTIVE: Until recently, best supportive care (BSC)
has been the only option for NSCLC patients who do not
respond to first line platinum based chemotherapy. Doce-
taxel was recently approved by NICE for use in patients
with locally advanced or metastatic lung cancer. This
study modeled the incremental cost-effectiveness of doce-
taxel and BSC versus BSC alone, in terms of direct
health-care costs per life year gained.
METHOD: The model used the results of a published
trial, which directly compared docetaxel plus BSC with
BSC alone. The difference in mean survival between the
docetaxel group and the BSC group was calculated as
3.82 months. Costs principally comprised drug acquisi-
tion and administration. In the reported trial result there
were no costs for toxicity treatment or any cost offsets,
because of incomplete trial data on non-chemotherapy
treatments. However, a worst case was modeled, includ-
ing possible toxicity treatment costs, and a best case, in-
cluding possible cost offsets. Sensitivity analysis also var-
ied months of life gained by taking the weighted average
of the worst two survival results (worst case) and the best
two survival results (best case) from four phase II trials.
Patient mean body mass and the number of vials used to
meet dose requirements were also varied.
RESULTS: The model estimated a cost per life year gained
of £13,618. (Best case £7,086; worst case £28,905). These
cost-effectiveness ratios compare favourably to accepted
standards in the UK. Whilst not captured in the model, the
published study showed no significant difference between
the docetaxel group and the BSC group in terms of quality
of life, but all QoL parameters favoured the docetaxel arm.
CONCLUSION: Docetaxel is a cost-effective treatment for
pre-treated NSCLC in terms of survival, with a non-signifi-
cant trend to improved quality of life compared to BSC.
PCN7
COST OF THE POST-PBPC REINFUSION
PERIOD IN HIGH DOSE TREATMENT OF
NON-HODGKIN’S FOLLICULAR LYMPHOMA 
(N-HFL) WITH AND WITHOUT FILGRASTIM
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1
1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, 
Pierre Bénite, France; 3Hôpital Brabois, Vandoeuvre les Nancy, 
France; 4Amgen Inc, Thousand Oaks, CA, USA
OBJECTIVES: to retrospectively assess the cost of treat-
ment following reinfusion of PBPC after high-dose che-
motherapy in n-HFL patients until day 90 post-reinfusion
in an open-label, randomised phase III trial comparing
the treatment with and without filgrastim. The study was
a multi-centre trial conducted in France between 1995–
1999.
METHODS: Of fifty-one patients enrolled, 27 received
filgrastim (FI) and 24 were in the control arm (C). Demo-
graphic and disease-specific information was collected
through the CRF. Costs measured were hospital duration
(normal ward and ICU), drugs, transfusions, diagnostics
and lab tests. Drug prices were retrieved from the VIDAL
2000 database and on-line BIAM database. Costs of hos-
pitalization and technical procedures were obtained from
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one participating centre. Costs were evaluated for the
first hospitalization period post-transplant (FP) and for
the total duration of the follow-up period (OP). All prices
are expressed in FRF 2000 currency. Due to the small
sample size non-parametric rank testing was used to de-
termine whether significant differences existed (p  .05,
two sided).
RESULTS: Average FP cost per patient was 245,603.4
FRF (SD: 92,950.1) for C and 218,131.8 FRF for FI (SD:
61,711.7). Cost difference was 27,352.9 FRF (11%) in fa-
vor of the filgrastim arm (p  .15). Average OP cost per
patient was 267,784.9 FRF for C and 244,974.6 FRF for
FI. The cost difference did not change during follow-up.
Main cost drivers were, as expected, the cost of hospital-
ization and of IV antibiotic drugs. On average, FI patients
leave the ICU 2.8 days earlier than P patients during FP.
CONCLUSION: Use of filgrastim 24 hours post-PBPC
following high dose chemotherapy for n-HFL patients
could result in important cost reductions, mainly attrib-
utable to a shorter hospitalization in ICU and a lower use
of IV-antibiotics.
PCN8
COST OF MANAGING SEVERE HYPERURICEMIA 
AND TUMOUR LYSIS SYNDROME IN 
HAEMATOLOGIC MALIGNANCIES
Annemans LJ1, Moeremans K2
1Ghent University, HEDM, Meise, Belgium; 2HEDM, Meise, 
Belgium
OBJECTIVES: Hyperuricemia (HU) and tumour lysis
syndrome (TLS) are important complications leading to
increased morbidity and mortality in patients with acute
lymphoid or myeloid leukaemia (ALL/AML) and non-
Hodgkin lymphoma (NHL). The objective was to calcu-
late incidence and average cost of managing HU and TLS
in current daily practice from the payer’s perspective.
METHODS: Seven hundred eighty eight patients, both
adults and children, from Belgium, Holland, Spain and
the UK, who received induction treatment between 1999
and 2000, were screened retrospectively for the occur-
rence of HU or TLS. In patients fulfilling predefined diag-
nostic criteria, HU or TLS-related resource use was re-
corded and costs calculated by applying local unit costs.
RESULTS: HU was detected in 18.9% of screened pa-
tients, TLS in 5.0% despite 79% prophylaxis. The aver-
age cost of HU in the absence of TLS was 672 Euro (SE 
181), of which 218 Euro were for medication and 376
Euro for the hospital stay. The average cost of TLS was
7,342 Euro (SE  1,412) of which 5,837 Euro was re-
lated to additional hospitalization, 719 to interventions
(mainly dialysis) and 446 Euro to medication. TLS pa-
tients requiring dialysis incurred an average cost of
17,706 Euro compared to 3,887 in non-dialysed TLS
cases. Inter-country differences in costs were observed
and were solely due to differences in unit costs. Age or
underlying malignancy had no significant impact on
management costs.
CONCLUSIONS: Rates of HU and TLS observed were
at the low end of the range compared to previously pub-
lished reports in specific indications. There is a large vari-
ation in costs, and distributions are highly skewed. Pa-
tients developing TLS incur 11 times greater costs than
patients with HU in whom development of TLS can be
prevented. The main cost driver in TLS patients is the
need for interventions (dialysis and haemofiltration) that
require ICU admission and extra hospital stay.
PCN9
COST-EFFECTIVENESS OF IMAGE-GUIDED 
VERSUS BLIND INSERTION OF HICKMAN LINES 
IN ADULT CANCER PATIENTS BY NURSES
Boland A1, Fitzsimmons L2, Haycox A1
1University of Liverpool, Liverpool, UK; 2Christie Hospital NHS 
Trust, Manchester, UK
OBJECTIVE: In the United Kingdom NHS, approxi-
mately 200,000 central venous catheters are inserted in
adult patients per year. The most frequently inserted cen-
tral venous catheter is the Hickman line. As the mean
cost of a Hickman line insertion is estimated to be £450,
the annual cost to the NHS is substantial.
METHODS: A prospective randomised controlled trial
was conducted at the Christie NHS Trust (UK) to com-
pare blind versus image-guided approaches to Hickman
line insertions. Blind insertions were performed at the pa-
tient’s bedside whilst image-guided insertions were per-
formed in the interventional x-ray suite. An incremental
cost-effectiveness analysis was carried out alongside the
clinical trial from the perspective of the NHS. Main clini-
cal outcome measures included pneumothorax, arterial
puncture and catheter tip misplacement. The primary
economic outcome of interest was the incremental cost
per misplaced catheter tip avoided.
RESULTS: There were no clinically or statistically signif-
icant differences in pneumothorax or arterial puncture
rates across the blind arm (n  235) and the image-
guided arm (n  235) of the trial. Catheter tip misplace-
ment occurred in 1% of image-guided insertions and in
14% of blind insertions. However, patient and profes-
sional perception of catheter tip misplacement appeared
to demonstrate that the difference was statistically signif-
icant rather than clinically significant. Economic evalua-
tion results concluded that the total cost of image-guided
insertion of Hickman lines (£110,000) was similar to that
of blind Hickman-line insertions (£104,000).
CONCLUSIONS: The study shows that the vast majority
of Hickman-line insertions can be successfully inserted
blind at the bedside by nurses. Nevertheless, image-
guided insertions may lead to greater clinical benefits for
some groups of patients. Economic evaluation results
demonstrate that image-guided insertions are more cost-
effective than blind insertions. However, cost-effective-
ness of the image-guided approach is limited by the avail-
ability of the interventional x-ray suite.
